Open AccessHepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients
Author(s) -
Rebecca Pastor,
François Habersetzer,
Samira FafiKremer,
Michel Doffoël,
Thomas F. Baumert,
JeanPierre Gut,
Françoise Stoll–Keller,
Évelyne Schvoerer
Publication year - 2009
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.15.753
Subject(s) - adefovir , virology , hepatitis b virus , hepatitis b , mutation , virus , biology , tenofovir , drug resistance , resistance mutation , polymerase chain reaction , medicine , reverse transcriptase , lamivudine , gene , genetics , human immunodeficiency virus (hiv)
Anti-hepatitis B virus (HBV) therapy leads to the emergence of mutant viral strains during the treatment of chronic hepatitis B with nucleos(t)ides analogues. The existence of HBV variants with primary antiviral resistance may be important for treatment choice. We studied two patients with chronic HBV infection by sequencing the HBV polymerase gene. They had adefovir- and tenofovir-related mutations in the viral polymerase, although they had never been treated. These mutations were rtV214A/rtN238T in one patient and rtA194T in the other. Thus, mutations in untreated patients deserve cautious surveillance. These data indicate that mutations that can theoretically confer adefovir or tenofovir resistance may emerge in treatment-naive patients.